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Recombinant adeno-associated viruses (rAAV) remain one of the most promising gene therapy vectors for 
patients with genetic abnormalities.  rAAV can safely deliver long-lasting expression of a therapeutic transgene. 
To create a rAAV virus the wild-type viral genome is replaced with a functional transgene expression cassette. A 
constitutive promoter can be utilized to drive strong expression of the transgene once the rAAV vector has 
infected the target cell. Unlike wtAAV, the recombinant vector avoids the pitfalls of genomic integration by 
establishing extrachomosomal episomes or concatemers.  Multiple studies have shown that rAAV can provide 
sustained expression of the transgene in cultured cells and pre-clinical models, providing evidence that rAAV 
could offer a cure for certain diseases. Bioengineering advancements have expanded the viral tropism beyond 
the constraints of naturally occurring AAV capsids, increasing the types of cells that can be thought of as 
targets. Taken together, rAAV therapies have attractive qualities to safely address the needs of patients where 
protein or small molecule therapies would fall short.   
 
One challenge with therapeutic rAAV is the ability to generate enough virus for clinical trials and commercial 
supply. This is particularly true with neuromuscular or hemophilia patients in which doses can exceed 1 x 1014 
viral genomes per patient. Typical yields from a rAAV production are around 104 viral genomes per cell, 
meaning 1010 cells will be needed for a single dose. This amount of therapeutic virus is a challenge to deliver 
with standard gene therapy production platforms, and will require a production platform that can reliably 
generate sufficient quantities of therapeutic rAAV to meet patient demand. Biogen has selected the producer 
cell line (PCL) platform to meet the large demand for therapeutic rAAV. Producer cell lines are generated by 
stably integrating the AAV viral genes along with the ITR flanked therapeutic gene of interest into a host cell line.  
rAAV production is then triggered by the addition of a ‘helper virus’ to provide functional genes for AAV 
replication. Traditional PCL platforms have used HeLa cells as the host and Adenovirus type-5 to deliver helper 
functions. We have used this platform as a basis for further development. Presented here will be our rationale 
for selecting the PCL platform, improvements made to the platform for ongoing clinical support, and our vision 
for the next generation PCL platform.  
 
